Myocardial infarction and individual nonsteroidal anti‐inflammatory drugs meta‐analysis of observational studies
Open Access
- 25 April 2013
- journal article
- review article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 22 (6) , 559-570
Abstract
Objective: To conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti‐inflammatory drugs (NSAIDs).Methods: A search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta‐analysis on 18 independent study populations.Results: Random‐effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94–1.20), followed by celecoxib 1.12 (1.00–1.24), ibuprofen 1.14 (0.98–1.31), meloxicam 1.25 (1.04–1.49), rofecoxib 1.34 (1.22–1.48), diclofenac 1.38 (1.26–1.52), indometacin 1.40 (1.21–1.62), etodolac 1.55 (1.16–2.06), and etoricoxib 1.97 (1.35–2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73–1.00); ibuprofen, 1.20 (0.97–1.48); celecoxib, 1.23 (1.00–1.52); diclofenac, 1.41 (1.08–1.86); and rofecoxib, 1.43 (1.21–1.66).Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with dose–response relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use ≤3 months was associated with an increased risk of AMI.Conclusions: Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 46 references indexed in Scilit:
- Stroke risk and NSAIDs: a systematic review of observational studiesPharmacoepidemiology and Drug Safety, 2011
- Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational StudiesPLOS Medicine, 2011
- Etiology of sudden death in the community: Results of anatomical, metabolic, and genetic evaluationAmerican Heart Journal, 2010
- Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trialsAnnals of the Rheumatic Diseases, 2007
- The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarctionHeart, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Cyclooxygenase‐2 inhibitors and coronary occlusion – exploring dose–response relationshipsBritish Journal of Clinical Pharmacology, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986